SL

Sarah Lin

VP, Regulatory Affairs

MindWalk Holdings

MindWalk Holdings Pipeline

DrugIndicationPhase
MW-101Major Depressive Disorder (MDD)Phase 2
MW-201Alzheimer's Disease (Agitation)Phase 1/2
MW-301Parkinson's Disease PsychosisPhase 1
MW-401Generalized Anxiety Disorder (GAD)Pre-clinical
MW-501Cognitive Impairment associated with Schizophrenia (CIAS)Pre-clinical